Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies
Abstract
Background: Data on platinum sensitivity of low‐grade serous ovarian carcinoma (LGSOC) in the upfront setting is lacking, and there is limited and contradictory information on chemotherapy responses in recurrent disease.Methods: Patients with LGSOC seen at a comprehensive cancer center from January 1, 1998 to September 30, 2021 were identified from institutional databases. Response to neoadjuvant chemotherapy (NACT) or adjuvant platinum‐based chemotherapy and to second‐ to fifth‐line regimens was retrospectively characterized by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Wilcoxon rank‐sum and two‐tailed Fisher exact tests were employed.Results: Of 50 patients, 12 received platinum doublets for suboptimal residual disease and 11 as NACT. Of 12 patients with suboptimal residual disease, seven (58%) achieved objective responses (five partial responses [PRs] and two complete responses); of the 11 patients who underwent NACT, one (9%) achieved a PR (p = .027). The 15 remaining patients had stable disease on first‐line platinum chemotherapy. Of 44 patients who recurred, 20 had RECIST‐evaluable responses to second‐line and 27 to third‐line chemotherapy. Objective response rates to platinum‐based chemotherapy were 22% (two of nine) in the second line and 10% (one of 10) in the third. In second and third lines, highest response rates were observed with nonplatinum chemotherapy with bevacizumab, at 100% (two of two) and 30% (three of 10), respectively.Conclusions: Primary platinum‐based chemotherapy has moderate activity in LGSOC and minimal activity in the recurrent setting, suggesting standard definitions of platinum sensitivity may not apply in LGSOC. In the second and third lines, nonplatinum chemotherapy/bevacizumab elicited the highest response rates.Keywords
This publication has 17 references indexed in Scilit:
- Inherited Mutations in Women With Ovarian CarcinomaJAMA Oncology, 2016
- Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneumBritish Journal of Cancer, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal CancerInternational Journal of Gynecological Cancer, 2014
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistantGynecologic Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Epidemiology of low-grade serous ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2008
- Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneumGynecologic Oncology, 2008
- Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the OvaryObstetrics & Gynecology, 2006
- Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potentialOncogene, 2004